PMDA safety announcement on cerebral amyloid angiopathy after human dried dura mater transplantation
「ヒト乾燥硬膜の移植既往のある「脳アミロイド血管症」発症者が報告されたことへの対応について」を掲載しました
Published: 2025-08-05 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2025-08-05, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted information on a response to reported cerebral amyloid angiopathy in people with a history of human dried dura mater transplantation. The title does not specify the response measures or establish a causal relationship.
Business Impact
People with a history of human dried dura mater transplantation may be affected by the response described in the announcement, but the title does not identify any specific measures.
Recommended Action
Review of the official Japanese notice could clarify the reported cases, the scope of the response, and any measures concerning people with this transplantation history.